06/14/2026
Managing a child’s diabetes is a 24/7 job—but a major new milestone is about to make it a whole lot easier for families. 💙
The FDA has officially cleared Dexcom’s Stelo Glucose Biosensor System, making it the first-ever over-the-counter (OTC) continuous glucose monitor (CGM) approved for children ages 2 and older.
Here is why this is such a game-changer for parents and caregivers:
No Prescription Needed: Families can now access life-changing CGM technology directly, removing traditional barriers to care.
Real-Time Tracking: The wearable sensor automatically measures glucose every 15 minutes, beaming the data straight to a parent’s smartphone app.
Convenience that Lasts: Each sensor can be worn for up to 15 days, meaning fewer disruptions and more peace of mind.
This milestone is also a massive win for modern medicine. It’s a powerful example of how Real-World Evidence (RWE) is being used to inform regulatory decisions, drive innovation, and bring safe, effective tools directly to the public.
Every child deserves access to the tools they need to manage their health—wherever they are. Ask Dr. Sills and Natalie about how this could help your family.
👉 Read the full FDA announcement here: https://www.fda.gov/news-events/press-announcements/fda-clears-first-over-counter-continuous-glucose-monitor-children
The U.S. Food and Drug Administration today cleared for marketing the first over-the-counter (OTC) continuous glucose monitor (CGM) for children, Dexcom Inc.’s Stelo Glucose Biosensor System, an integrated CGM (iCGM) indicated for people two years of age and older who do not use insulin.